Privi Speciality Chemicals Limited has received an observation letter containing a ‘no objection’ from the BSE regarding its proposed scheme of amalgamation. The plan involves the merger of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company. This strategic move, which remains subject to further regulatory and statutory approvals, marks a significant step forward in the consolidation of its corporate structure.
Advancing the Amalgamation Process
Privi Speciality Chemicals Limited has reached a key milestone in its reorganization strategy. On May 06, 2026, the company formally announced the receipt of an observation letter from the BSE, confirming their ‘no objection’ to the proposed scheme of amalgamation. This follows a similar approval previously received from the National Stock Exchange of India Limited.
Details of the Proposed Merger
The restructuring involves the merger of two entities: Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, into Privi Speciality Chemicals Limited. This proposal, which was initially approved by the Board of Directors on December 19, 2025, aims to consolidate operations and streamline the organizational framework of the group.
Next Steps
While the company has secured necessary clearances from major stock exchanges, the scheme of amalgamation remains subject to final regulatory and statutory approvals. The company continues to move forward with the necessary legal procedures to finalize the integration of these entities, further strengthening its market position in the speciality chemicals sector.
Source: BSE
